APA (7th ed.) Citation

NA, T., E, W., R, L., T, A., R, R., C, A., . . . M, B. (2026). Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 123(5), e2515790122. https://doi.org/10.1073/pnas.2515790122

Chicago Style (17th ed.) Citation

NA, Traphagen, et al. "Lack of Synergy Between AR-targeted Therapies and PARP Inhibitors in Homologous Recombination-proficient Prostate Cancer." Proceedings of the National Academy of Sciences of the United States of America 123, no. 5 (2026): e2515790122. https://doi.org/10.1073/pnas.2515790122.

MLA (9th ed.) Citation

NA, Traphagen, et al. "Lack of Synergy Between AR-targeted Therapies and PARP Inhibitors in Homologous Recombination-proficient Prostate Cancer." Proceedings of the National Academy of Sciences of the United States of America, vol. 123, no. 5, 2026, p. e2515790122, https://doi.org/10.1073/pnas.2515790122.